Impact of Cardiovascular, Renal and Metabolic Comorbidities on Activity and Health-Related Quality of Life in Patients with Metabolic Dysfunction-Associated Steatohepatitis in France, Italy, Germany, and Canada
Author(s)
Jens U Marquardt, MD, PhD1, Giada Sebastiani, MD, PhD2, Riku Ota, MPH3, Eliza Smith, MBiochem (Hons)4, Kathryn Tebbs, MSc4, Emily Quinones, BSc (Hons)4, Hayley Wallinger, BSc (Hons)4, Elisabetta Bugianesi, MD, PhD5;
1University of Lübeck, Department of Medical Sciences, Lübeck, Germany, 2McGill University, Montreal, QC, Canada, 3Novo Nordisk, Global Payer Evidence Lead, Brøndby, Denmark, 4Adelphi Real World, Bollington, United Kingdom, 5University of Torino, Torino, Italy
1University of Lübeck, Department of Medical Sciences, Lübeck, Germany, 2McGill University, Montreal, QC, Canada, 3Novo Nordisk, Global Payer Evidence Lead, Brøndby, Denmark, 4Adelphi Real World, Bollington, United Kingdom, 5University of Torino, Torino, Italy
Presentation Documents
OBJECTIVES: Cardiovascular, renal and metabolic (CVRM) comorbidities are commonly associated with metabolic dysfunction-associated steatohepatitis (MASH). As data are limited on these comorbidities, we aimed to describe their impact on patient-reported health-related quality of life (HRQoL).
METHODS: Data were drawn from the Adelphi Real World MASH Disease Specific Programme™, a cross-sectional survey of physicians and MASH patients in France, Germany, Italy and Canada from January-June 2024. Physicians reported patient demographics and clinical characteristics. Patients self-reported HRQoL via the EQ-5D-5L (German tariff) and NASH-CHECK. NASH-CHECK scores range from 0 (least) to 10 (most impact). EQ-5D-5L utility scores range from 0-1; higher scores indicate better HRQoL. Patients were grouped by physician-stated fibrosis stage and presence of CVRM comorbidities: early fibrosis without comorbidities (EFnoC); early fibrosis with ≥1 comorbidity (EFwC); and advanced fibrosis with ≥1 comorbidity (AFwC). EFwC and AFwC groups were compared using pairwise statistics against the EFnoC control group after entropy balancing on patient age and sex.
RESULTS: Overall, 247 physicians reported data for 2675 patients, of whom 831 self-reported data. For EFnoC (n=170), EFwC (n=1575) and AFwC (n=478), respectively, mean±SD age was 50.6±10.8, 54.7±11.3 and 60.4±11.6 years 46.5%, 41.0% and 37.2% were female., and body mass index of 26.9±2.5kg/m2, 33.2±6.3kg/m2 and 34.2±7.8kg/m2. Of patients which self-reported data (n=48, n=536 and n=117, EFnoC, EFwC and AFwC respectively), mean EQ-5D-5L utility scores were lower for EFwC and AFwC patients (0.85±0.16 and 0.81±0.18) than EFnoC (0.90±0.12; p<0.01). EFwC patients had greater impact to NASH-CHECK Activity Limitations Scale domain (2.4±1.9) than EFnoC patients (p<0.05). AFwC patients had greater impact to Activity Limitations Scale (3.4±2.2), Fatigue (4.2±2.8) and Cognitive Symptom Scale (2.4±2.4) domains than EFnoC (1.8±1.8, 2.7±2.4 and 1.3±1.6, respectively; p<0.01).
CONCLUSIONS: Presence of additional CVRM comorbidities impacted patient HRQoL and activity, highlighting the need for improved management strategies in MASH patients.
METHODS: Data were drawn from the Adelphi Real World MASH Disease Specific Programme™, a cross-sectional survey of physicians and MASH patients in France, Germany, Italy and Canada from January-June 2024. Physicians reported patient demographics and clinical characteristics. Patients self-reported HRQoL via the EQ-5D-5L (German tariff) and NASH-CHECK. NASH-CHECK scores range from 0 (least) to 10 (most impact). EQ-5D-5L utility scores range from 0-1; higher scores indicate better HRQoL. Patients were grouped by physician-stated fibrosis stage and presence of CVRM comorbidities: early fibrosis without comorbidities (EFnoC); early fibrosis with ≥1 comorbidity (EFwC); and advanced fibrosis with ≥1 comorbidity (AFwC). EFwC and AFwC groups were compared using pairwise statistics against the EFnoC control group after entropy balancing on patient age and sex.
RESULTS: Overall, 247 physicians reported data for 2675 patients, of whom 831 self-reported data. For EFnoC (n=170), EFwC (n=1575) and AFwC (n=478), respectively, mean±SD age was 50.6±10.8, 54.7±11.3 and 60.4±11.6 years 46.5%, 41.0% and 37.2% were female., and body mass index of 26.9±2.5kg/m2, 33.2±6.3kg/m2 and 34.2±7.8kg/m2. Of patients which self-reported data (n=48, n=536 and n=117, EFnoC, EFwC and AFwC respectively), mean EQ-5D-5L utility scores were lower for EFwC and AFwC patients (0.85±0.16 and 0.81±0.18) than EFnoC (0.90±0.12; p<0.01). EFwC patients had greater impact to NASH-CHECK Activity Limitations Scale domain (2.4±1.9) than EFnoC patients (p<0.05). AFwC patients had greater impact to Activity Limitations Scale (3.4±2.2), Fatigue (4.2±2.8) and Cognitive Symptom Scale (2.4±2.4) domains than EFnoC (1.8±1.8, 2.7±2.4 and 1.3±1.6, respectively; p<0.01).
CONCLUSIONS: Presence of additional CVRM comorbidities impacted patient HRQoL and activity, highlighting the need for improved management strategies in MASH patients.
Conference/Value in Health Info
2025-05, ISPOR 2025, Montréal, Quebec, CA
Value in Health, Volume 28, Issue S1
Code
PCR249
Topic
Patient-Centered Research
Topic Subcategory
Health State Utilities, Patient-reported Outcomes & Quality of Life Outcomes
Disease
SDC: Diabetes/Endocrine/Metabolic Disorders (including obesity), SDC: Gastrointestinal Disorders